Clifutinib besylate - HEC Pharm
Alternative Names: Clifutinib; HEC-73543Latest Information Update: 30 Sep 2024
At a glance
- Originator HEC Pharm
- Developer Sunshine Lake Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
Most Recent Events
- 03 Mar 2023 Phase-III clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In adults, In the elderly) in China (PO) (NCT05586074)
- 08 Dec 2022 Sunshine Lake Pharma completes a phase I PK trial (In volunteers) in China (NCT05454098)
- 08 Nov 2022 Sunshine Lake Pharma initiates a phase I PK trial (In volunteers) in China (NCT05454098)